Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Sensitive Metastatic Prostate Cancer”

145 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 145 results

Testing effectiveness (Phase 2)Study completedNCT05059236
What this trial is testing

Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 223
Early research (Phase 1)Study completedNCT04712396
What this trial is testing

Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Who this might be right for
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
AstraZeneca 11
Not applicableStudy completedNCT01233557
What this trial is testing

Biomarkers of Bone Resorption in Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
University of Aberdeen 40
Testing effectiveness (Phase 2)Study completedNCT02059213
What this trial is testing

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
University of Michigan Rogel Cancer Center 72
Testing effectiveness (Phase 2)UnknownNCT06134271
What this trial is testing

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Jianbin Bi 160
Not applicableLooking for participantsNCT07052578
What this trial is testing

Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

Who this might be right for
Prostate Cancer
AstraZeneca 400
Testing effectiveness (Phase 2)WithdrawnNCT06392841
What this trial is testing

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene Mutation+7 more
Qian Qin
Not applicableStudy completedNCT05901649
What this trial is testing

The Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Janssen-Cilag Ltd. 505
Large-scale testing (Phase 3)UnknownNCT03879122
What this trial is testing

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Spanish Oncology Genito-Urinary Group 135
Not applicableActive Not RecruitingNCT06865547
What this trial is testing

ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide

Who this might be right for
Prostate Cancer (Adenocarcinoma)
Yonghong Li 94
Not applicableStudy completedNCT06452212
What this trial is testing

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Korea, Inc. 23
Not applicableLooking for participantsNCT07181122
What this trial is testing

Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Ankara Etlik City Hospital 102
Early research (Phase 1)WithdrawnNCT05567770
What this trial is testing

ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer

Who this might be right for
Prostate Cancer Metastatic
Weill Medical College of Cornell University
Not applicableStudy completedNCT02376296
What this trial is testing

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Saladax Biomedical, Inc. 35
Testing effectiveness (Phase 2)UnknownNCT05461261
What this trial is testing

The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Hormone Sensitive Metastatic Prostate CancerDNA Damage Repair DeficiencyChemotherapy Effect+1 more
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 50
Early research (Phase 1)Not Yet RecruitingNCT06099990
What this trial is testing

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd. 660
Early research (Phase 1)Study completedNCT04477512
What this trial is testing

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Washington University School of Medicine 18
Testing effectiveness (Phase 2)Looking for participantsNCT07005154
What this trial is testing

Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 218
Testing effectiveness (Phase 2)Active Not RecruitingNCT06991556
What this trial is testing

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Novartis Pharmaceuticals 168
Not applicableStudy completedNCT06498921
What this trial is testing

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 106
Next Page